HIV Pre-exposure Prophylaxis (PrEP) Implementation Science in CDC-funded Public Health Demonstration Projects (Admin Supp) | Apply Online

Frequently Asked Questions (FAQs)

What is the title and identifier of this funding opportunity?

The opportunity is titled "HIV Pre-exposure Prophylaxis (PrEP) Implementation Science in CDC-funded Public Health Demonstration Projects (Admin Supp)" and is identified as PA-16-199.

Which agency is offering this funding?

This is an HHS/NIH opportunity, offered through NIH and specifically associated with NIMH as an administrative supplement announcement.

What type of funding is this?

It is an NIH administrative supplement (not a standalone, new independent award). It is also described as a discretionary grant opportunity in the health category.

What is the main purpose of the supplement?

The purpose is to strengthen real-world PrEP delivery by embedding implementation science research within ongoing, CDC-supported public health demonstration projects, with the broader goal of reducing new HIV infections.

Who is the primary public health focus population?

The opportunity emphasizes improving PrEP implementation to help reduce new HIV infections among men who have sex with men (MSM) and transgender individuals.

Is this opportunity about testing whether PrEP works clinically?

No. The announcement explicitly distinguishes implementation research from clinical efficacy testing, noting that PrEP efficacy is already established. The focus is on how to make PrEP programs work better in real public health settings and at scale.

What kind of research is expected under this supplement?

The proposed work must be implementation science. That means studying practical, real-world questions about planning, promotion, and delivery of PrEP in public health settings, rather than basic efficacy questions.

What are examples of implementation science topics that fit this supplement?

Examples highlighted include how clinics and health departments adopt PrEP workflows; how they reach priority populations; how they support adherence and persistence; how they reduce drop-off at each step of the PrEP continuum; and how they address barriers such as stigma, access, navigation, insurance, and coordination between testing services and prescribing providers.

What CDC initiative must the supplement leverage?

The supplement must be built around a genuine collaborative partnership with public health departments already running PrEP demonstration projects funded under CDC Funding Opportunity Announcement CDC-RFA-PS15-1506, known as CDC Project PrIDE.

Can an applicant propose a standalone PrEP program under this supplement?

No. The supplement is intended to leverage and learn from an existing CDC Project PrIDE demonstration project rather than create a standalone PrEP program.

What does "genuine collaborative partnership" mean in this context?

Based on the announcement description, it means the applicant must actively partner with public health departments that are already operating CDC-funded PrEP demonstration projects, so the research is embedded within and informed by those ongoing real-world efforts.

Can the proposed research duplicate evaluation work already required by the CDC demonstration projects?

No. The announcement states that proposed research cannot duplicate evaluation activities that the CDC demonstration projects are already planning or required to conduct. The supplement should add distinct, research-oriented implementation science questions and methods that complement (but do not repeat) routine program evaluation.

How should the supplement relate to an applicant's existing NIH grant?

Because this is an administrative supplement, the proposed work must remain consistent with the scientific aims of the applicant's existing "parent" NIH grant. The supplement needs to fit logically within the scope of the current NIH-funded research program.

Who is this opportunity most suited for?

In practical terms, it is aimed at researchers who already have NIH funding and who can partner directly with CDC Project PrIDE jurisdictions to produce actionable evidence on improving PrEP implementation for MSM and transgender communities.

What is the maximum award amount (ceiling) for the supplement?

The award ceiling listed is $175,000, which indicates the maximum amount that could be requested for the supplement.

What is the CFDA number associated with this opportunity?

The opportunity is listed under CFDA 93.242.

What is the application deadline for this opportunity?

The original and current closing date listed is June 15, 2016, indicating it was a time-limited call for FY2016 supplement applications.

What kinds of organizations are eligible to apply?

Eligibility is described as broad and includes (among others): state, county, and city governments; public and private institutions of higher education; federally recognized tribal governments and other tribal organizations; public housing authorities; nonprofits with and without 501(c)(3) status; for-profit organizations other than small businesses; and small businesses.

Does this opportunity involve public health departments directly?

Yes. A key requirement is collaborating with public health departments that are already operating CDC-funded PrEP demonstration projects under CDC Project PrIDE.

What is the expected value of the work produced by this supplement?

The emphasis is on generating actionable knowledge that can improve public health practice, strengthen PrEP service delivery models, and accelerate reductions in HIV incidence by making PrEP easier to access, start, and sustain in real-world settings.